ASTRUM-005

NCT04063163 📎

Regimen

Experimental
serplulimab (HLX10) + carboplatin + etoposide
Control
placebo + carboplatin + etoposide

Population

Previously untreated extensive-stage small-cell lung cancer

Key finding

mOS 15.4 vs 10.9 mo (HR 0.63, 95% CI 0.49-0.82, P<0.001); mPFS 5.7 vs 4.3 mo (HR 0.48, 95% CI 0.38-0.59)

Source: PMID 36166026

Timeline

    Guideline citations

    • CSCO SCLC 2025 (p.37)⚠️ OCR source